
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics is a clinical-stage precision medicine company with a strong pipeline of medicine candidates in precision oncology and genetic disease. The company utilizes its Dynamo platform, which integrates computational and experimental approaches, to target previously intractable or inadequately addressed drug-protein targets. The recent positive top-line data for zovegalisib, with a 60% volumetric response rate and excellent tolerability, positions the company to potentially challenge existing treatments and expand into new patient populations. With a solid financial position and potential for significant growth, there is optimism for Relay Therapeutics' stock and its ability to bring life-changing therapies to patients.
Bears say
Relay Therapeutics is a clinical-stage precision medicine company with a pipeline of potential therapies for precision oncology and genetic diseases. However, despite positive feedback from ISSVA suggesting that their drug zovegalisib is an improvement over other treatments, including potential accelerated approval in a large market, there are still concerns about potential side effects and mixed results in clinical data. Additionally, the company may face financial risks in the future as they seek additional funding for drug development, which could create dilution risk for existing shareholders.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares